Limits...
Comparison of Korean COPD guideline and GOLD initiative report in term of acute exacerbation: a validation study for Korean COPD guideline.

Hwang YI, Park YB, Oh YM, Lee JH, Kim TH, Yoo KH, Yoon HK, Rhee CK, Kim DK, Shin KC, Lee SY, Jung KS - J. Korean Med. Sci. (2014)

Bottom Line: There was no one who experienced exacerbation during the first year of follow-up in the Korean group 'ga'.The 12-month exacerbation rates of Korean group 'na' and 'da' were 4.5% and 16.0%, respectively (P<0.001).A total of 16.0% of the patients who were reclassified from GOLD A to Korean group 'da' experienced acute exacerbation,and 15.3% from GOLD B to Korean group 'da' experienced acute exacerbation.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea.

ABSTRACT
The purpose of this study was to compare the Korean COPD guideline to GOLD consensus report in terms of acute exacerbation. A total of 361 patients were enrolled in this study, and 16.9% of them experienced acute exacerbation during the follow-up. A total of 6.3% of patients in GOLD A, 9.5% in GOLD B, 7.7% in GOLD C and 17.0% of GOLD D experienced exacerbation during the first year of follow-up, respectively (P=0.09). There was no one who experienced exacerbation during the first year of follow-up in the Korean group 'ga'. The 12-month exacerbation rates of Korean group 'na' and 'da' were 4.5% and 16.0%, respectively (P<0.001). We explore the experience of exacerbation in patients with change of their risk group after applying Korean COPD guideline. A total of 16.0% of the patients who were reclassified from GOLD A to Korean group 'da' experienced acute exacerbation,and 15.3% from GOLD B to Korean group 'da' experienced acute exacerbation. In summary, the Korean COPD guideline is useful to differentiate the high risk from low risk for exacerbation in terms of spirometry. This indicates that application of Korean COPD guideline is appropriate to treat Korean COPD patients.

Show MeSH

Related in: MedlinePlus

Proportion of patients with exacerbation according to each classification system during the first year of follow-up.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4129203&req=5

Figure 3: Proportion of patients with exacerbation according to each classification system during the first year of follow-up.

Mentions: A total 16% of Korean group 'da' patients experienced exacerbation during the first year of follow-up. However, none of Korean group 'ga' patients experienced had exacerbation and 4.5% of Koran group 'na' patients experienced exacerbation during the same period. The first year exacerbation rate was 6.3% for GOLD A, 9.5% for GOLD B, 7.7% for GOLD C and 17% for GOLD D, respectively (P=0.09) (Fig. 3). During the follow-up period, 14.3% of patients reassigned into GOLD A experienced exacerbation. A total 13.5% of patients with GOLD B, 23.1% of GOLD C and 20.1% of GOLD D experienced exacerbation. This figure was not statistically significant. The proportions of the patients who experienced exacerbation during the same period according to the Korean COPD classification were 7.9% in Korean group 'ga', 6.0% in Korean group 'na', and 21.1% in Korean group 'da', respectively (P=0.004).


Comparison of Korean COPD guideline and GOLD initiative report in term of acute exacerbation: a validation study for Korean COPD guideline.

Hwang YI, Park YB, Oh YM, Lee JH, Kim TH, Yoo KH, Yoon HK, Rhee CK, Kim DK, Shin KC, Lee SY, Jung KS - J. Korean Med. Sci. (2014)

Proportion of patients with exacerbation according to each classification system during the first year of follow-up.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4129203&req=5

Figure 3: Proportion of patients with exacerbation according to each classification system during the first year of follow-up.
Mentions: A total 16% of Korean group 'da' patients experienced exacerbation during the first year of follow-up. However, none of Korean group 'ga' patients experienced had exacerbation and 4.5% of Koran group 'na' patients experienced exacerbation during the same period. The first year exacerbation rate was 6.3% for GOLD A, 9.5% for GOLD B, 7.7% for GOLD C and 17% for GOLD D, respectively (P=0.09) (Fig. 3). During the follow-up period, 14.3% of patients reassigned into GOLD A experienced exacerbation. A total 13.5% of patients with GOLD B, 23.1% of GOLD C and 20.1% of GOLD D experienced exacerbation. This figure was not statistically significant. The proportions of the patients who experienced exacerbation during the same period according to the Korean COPD classification were 7.9% in Korean group 'ga', 6.0% in Korean group 'na', and 21.1% in Korean group 'da', respectively (P=0.004).

Bottom Line: There was no one who experienced exacerbation during the first year of follow-up in the Korean group 'ga'.The 12-month exacerbation rates of Korean group 'na' and 'da' were 4.5% and 16.0%, respectively (P<0.001).A total of 16.0% of the patients who were reclassified from GOLD A to Korean group 'da' experienced acute exacerbation,and 15.3% from GOLD B to Korean group 'da' experienced acute exacerbation.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea.

ABSTRACT
The purpose of this study was to compare the Korean COPD guideline to GOLD consensus report in terms of acute exacerbation. A total of 361 patients were enrolled in this study, and 16.9% of them experienced acute exacerbation during the follow-up. A total of 6.3% of patients in GOLD A, 9.5% in GOLD B, 7.7% in GOLD C and 17.0% of GOLD D experienced exacerbation during the first year of follow-up, respectively (P=0.09). There was no one who experienced exacerbation during the first year of follow-up in the Korean group 'ga'. The 12-month exacerbation rates of Korean group 'na' and 'da' were 4.5% and 16.0%, respectively (P<0.001). We explore the experience of exacerbation in patients with change of their risk group after applying Korean COPD guideline. A total of 16.0% of the patients who were reclassified from GOLD A to Korean group 'da' experienced acute exacerbation,and 15.3% from GOLD B to Korean group 'da' experienced acute exacerbation. In summary, the Korean COPD guideline is useful to differentiate the high risk from low risk for exacerbation in terms of spirometry. This indicates that application of Korean COPD guideline is appropriate to treat Korean COPD patients.

Show MeSH
Related in: MedlinePlus